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Abstract 12 
BAP1 (BRCA-associated-protein-1) is mutated in several cancers and a few therapies 13 
targeting BAP1 loss-of-function mutations have been proposed, some of them being already 14 
tested in clinical trials. However, most of missense mutations have not been functionally 15 




BRCA-associated protein 1 (BAP1) gene, encoding for a deubiquitinating enzyme (DUB), is 18 
frequently altered in several tumors, including mesothelioma, uveal melanoma and renal 19 
cancer, and germline BAP1 mutations lead to BAP1-dependent tumor predisposition 20 
syndrome (OMIM #603089) (reviewed in [1]). BAP1 and BRCA1/2, although differing in 21 
their tissue tropism, share their involvement in ubiquitin regulation and DNA damage repair 22 
[2] and show several similarities, as discussed below, in the context of the implication of 23 
their mutations in cancer. 24 
According to COSMIC database, roughly half of BAP1 mutations induce frameshift causing 25 
loss-of-function, and most of the remaining are missense mutations leading to amino acid (aa) 26 
changes. In this Forum, we present an overview of the current understanding of BAP1 27 
structural domains and of the few BAP1 missense mutations that have been functionally 28 
characterized. With this knowledge, we propose ways to prioritize the characterization of the 29 
remaining mutations in order to better understand the role of BAP1 as a cancer predisposing 30 
gene. For example, they may help understand improved survival in familial malignant 31 
mesothelioma (MM) patients bearing BAP1 mutations, relative to other MM cohorts [3]. 32 
BAP1 is a 729 aa long protein that possesses an ubiquitin carboxy-terminal hydrolase (UCH) 33 
domain at its N-terminus, followed by a short UCH37-like coiled coil motif (ULD1, also 34 
called CC1), an internal domain (ID), and at its C-terminus, a second long ULD2 (CC2), two 35 
nuclear localization signals (NLS1 and 2) and a C-terminal tail (CT, Figure 1a). 36 
 37 
BAP1 missense mutations and their biological consequences 38 
BAP1 plays a complex role as a transcription regulator, chromatin modulator, and, as 39 
mentioned above, has been shown to be implicated in DNA repair (reviewed in [1]). For its 40 
DUB function on chromatin, BAP1 has been suggested to form a double heterodimer [4] with 41 
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Additional Sex Comb Like (ASXL) family of epigenetic regulators [4] frequently mutated in 42 
cancer. 43 
Unfortunately, only 38 BAP1 amino acids mutations have been functionally characterized 44 
(Supplementary Table 1) although 588 BAP1 gene missense mutations, some of them 45 
occurring at the same residue resulting in mutations in 291 aa have been reported in COSMIC 46 
database (July 2019, Figures 1b, n=587) or classified as pathogenic in ClinVar database 47 
(n=1). UCH domain is the most frequently mutated (Figure 1c), thus potentially affecting 48 
BAP1 enzymatic activity. Therefore, functional studies have been mostly carried out on these 49 
mutations. The importance of characterizing these mutant variants is highlighted by the fact 50 
that it is difficult to predict their biological consequences. For example, BAP1 self-51 
deubiquitination is necessary for nuclear translocation [5], therefore, mutations within UCH 52 
domain abolishing its enzymatic activity might prevent BAP1 nuclear localization and 53 
function. However, some UCH mutants with diminished enzymatic activity were described to 54 
efficiently localize to the nucleus (A95D, C91A [6], Supplementary Table 1). Sequences 55 
alignment between protein homologs from different species or between protein members of 56 
the same family, are often used to predict aa that are functionally important. Alignment of 57 
UCH, ULD1 and ULD2 domains of the human BAP1 sequence with other UCH family 58 
members, especially with UCH37 (also called UCHL5), sharing close homology with BAP1 59 
within UCH and ULD regions, and the Drosophila ortholog of BAP1, Calypso, which allowed 60 
structural characterization [4, 7], highlights the presence of potentially pathogenic mutations 61 
affecting conserved amino acids (Figure 1d). 61 out of 113 (54%) of these conserved sites 62 
(considering only “*” and “:” marked sites) are reported as missense substitutions in 63 
COSMIC database. However, barely a quarter of them have been functionally investigated. 64 
Therefore, it is of great importance to verify all mutations predicted to have an impact on 65 
BAP1 functions, because of their possible dominant-negative action in the presence of one 66 
copy of the BAP1 wild-type (WT) allele. Indeed, several studies have documented that loss of 67 
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one BAP1 allele matters [8] and germline BAP1 mutations accelerate neoplastic 68 
transformation in mice exposed to asbestos (reviewed in [1]). C91S mutant was shown to 69 
have a dominant effect on cell growth (reviewed in [1]). C91 is in the active site (Figure 1d) 70 
and tamoxifen-induction of C91A BAP1 expression in Bap1 
C91A/-
 adult mice leads to the 71 
same dysfunction of hematopoiesis, liver and pancreas as observed for tamoxifen-induced 72 
BAP1 deficiency [9], proving the essential role of the catalytic function. Other BAP1 73 
mutations (I47F, F81V, A95D) were reported to potentially cause a dominant-negative effect 74 
[10]. This is likely linked to the fact that BAP1 was suggested to function as a 2:2 or 2:1 75 
dimer with ASLX [4, 11] in the context of H2A deubiquitination (Figure 1e, left upper panel.  76 
For matter of simplicity, only the 2:1 model is shown). This process is important for the 77 
regulation of chromatin-remodeling and gene expression [12, 13]. It is yet unknown whether 78 
other BAP1 functions require the same structural organisation and this model remains a 79 
matter of controversy based on findings on Calypso [7], therefore, the 1:1 model is also 80 
represented (Figure 1e, left lower panel). In the 2 molecules of BAP1/assembly model, in case 81 
where both BAP1 WT and mutant proteins are equally abundant, one could envision a 82 
scenario, in which BAP1 WT dimerizes with BAP1 mutant protein (Figure 1e, upper middle 83 
panel). In this configuration, the presence of BAP1 mutant may result in the inhibition of 84 
BAP1 DUB activity. Dominant-negative activity can be achieved when BAP1 mutant 85 
containing dimers suppress the effect of the BAP1 WT dimers, by failing to exert 86 
deubiquitination, while still capable of stable interaction with their target proteins. At least 87 
one BAP1 mutant, S63C, shows an increased enzymatic activity, same ability to relocalize to 88 
DNA damage site as WT, and provides survival advantage after double strand break damage 89 
compared to loss-of-function UCH mutants (Supplementary Table 1). A possible gain of 90 
function might therefore be expected by S63C: WT BAP1 dimer formation.  91 
It is important to keep in mind that BAP1 haploinsufficiency can be triggered in a 92 
physiological manner through expression of a 12 aa shorter BAP1 transcript (BAP1Δ), 93 
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missing a fragment covering parts of the UCH and ULD1 domains (missing fragment 94 
incurring in isoform BAP1Δ is represented in Figure 1a). When BAP1Δ is abundant, it may 95 
confer a dominant-negative role over the full-length BAP1 (Figure 1e, upper right panel). An 96 
expression of BAP1Δ representing at least 20% of total BAP1 leads to impaired overall BAP1 97 
UCH activity and increased sensitivity to PARPi in mesothelioma cancer cells [14]. 98 
Interestingly, an opposite situation has been suggested for BRCA1, where high expression 99 
levels of a splice variant (BRCA1 Δ11q) confers resistance to PARPi [15], indicating that 100 
alternative splicing of both BAP1 and BRCA1 modifies therapy response.  101 
In the 1:1 model (Figure 1e, lower middle and right panel) mutated BAP1 or BAP1Δ 102 
competition with WT BAP1 would depend on the relative amount and complex stability.  103 
 104 
Concluding Remarks 105 
The question arises as to whether all reported missense mutations should be functionally 106 
characterized. Characterization of bona fide pathogenic mutations identified in BRCA1 or 107 
BRCA2 tumor suppressor genes has consequences on patients handling, allowing for more 108 
precise targeting. A similar situation is likely to be true for BAP1. However, it would be 109 
necessary to prioritize mutations to be investigated. This would allow also identifying 110 
whether yet uncharacterized mutations act like the S63C gain-of-function mutant mentioned 111 
above. Therefore, instead of focusing on mutations occurring in conserved amino acids, one 112 
could concentrate on hot spots (here defined as >4 cases reported in COSMIC database, 113 
residues labelled in Figure 1b), where so far only 9 out of 24 have been functionally 114 
characterized. It is noteworthy that sequence alignment of UCH family does not allow 115 
predicting functional importance of ID and CT mutants, which represent 31% of missense 116 
mutations, since these domains are present only in BAP1. For this analysis alignment of 117 
BAP1 sequence from different species is necessary (Supplementary Figure 1) and reveals that 118 
6 
 
15 out of 50 conserved residues (30%) are reported as missense substitutions in COSMIC 119 
database. None of them has been functionally characterized yet. 120 
In conclusion, a broader characterization of specific BAP1 mutations stands behind a better 121 
understanding of the biological consequences and therefore better design of the therapeutic 122 
options for patients.  123 
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Figure Legends 171 
 172 
Figure 1. (a) Representation of BAP1 structure. Missing residues in isoform BAP1Δ are also 173 
represented. (b) Occurrence of point missense mutations within BAP1 gene listed in COSMIC 174 
database (July 2019). (c) Frequency of point missense mutations per residue within each 175 
single BAP1 domain, here defined as: UCH domain (1-235 aa), ULD1 (236-255 aa), ID, 176 
internal -domain (256-634 aa), ULD2 (635-703 aa) and CT (704-729 aa). Ratio between 177 
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number of mutations occurring in each of above domains and domain's length was calculated 178 
and each ratio was assessed as percentage of the sum of ratio of all domains. (d) Alignment of 179 
BAP1 and other UCH family members including UCHL5 (UCH37) performed by Clustal 180 
Omega online tool. Conservative sites are indicated as follows: conserved sites (*), sites with 181 
conservative replacements (:), sites with semi-conservative replacements (.). Rectangles in 182 
green highlight mutations functionally characterized in a wet-lab settings (References 183 
documented in Supplementary Table 1). In orange residues forming the catalytic site of 184 
BAP1. In black are mutations predicted to be highly pathogenic based on segregation within 185 
carriers with BAP1 tumor predisposition syndrome (References documented in 186 
Supplementary Table 1), or listed as pathogenic in ClinVar database, or inferred of being 187 
functionally important, based on structural analysis of Calypso/Asx [7]. Importantly, the 188 
mutations that are in non-conserved sequences when comparing BAP1 and other UCH family 189 
members remain nevertheless conserved when comparing all BAP1 sequences from all 190 
species. (e) Schematic representation of possible complex assembly of BAP1 with ASLX 191 
taking into account the presence of 2 BAP1 [4, 11] or 1 BAP1 molecule/complex [7]. 192 
